B
Bull
Bull · 25%MENS
$11.92
Szenariopreis
$2.370
+0.072 (+3.04%)Zum Schluss
Loading chart…
- High
- 2.420
- Open
- 2.300
- VWAP
- 2.36
- Vol
- 22.35K
- Mkt Cap
- —
- Low
- 2.300
- Amount
- 52.82K
- EV/EBITDA, TTM
- 0.00
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
AI analysis of Jyong Biotech Ltd (MENS)
buyJyong Biotech Ltd is a good buy right now due to its recent clinical trial success, which showed a 27.3% reduction in prostate cancer incidence, and a current price of $2.37, which is significantly lower than its historical SMA of $5.798. However, the company has a high RSI of 87.629, indicating it may be overbought in the short term, which is a risk to consider.
Bewertungskennzahlen
The current forward P/E ratio for Jyong Biotech Ltd (MENS) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for MENS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
7.507-23NewsfilterJyong Biotech Reaffirms Focus on Global Licensing Partnerships in Urology
- 8.505-29Newsfilter
Jyong Biotech's Strategic Vision for Plant-Derived Therapies
- 9.505-15Newsfilter
Jyong Biotech Releases Annual Report for 2025
- 8.504-28Newsfilter
Jyong Biotech Advances Market Access Strategies for Plant-Based Drugs
- 9.003-27Newsfilter
Jyong Biotech Updates on MCS®-2 Clinical Progress
MENS FAQ — answered by Alphio AI
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer. It operates in the Healthcare sector.
Jyong Biotech Ltd is a good buy right now due to its recent clinical trial success, which showed a 27.3% reduction in prostate cancer incidence, and a current price of $2.37, which is significantly lower than its historical SMA of $5.798. However, the company has a high RSI of 87.629, indicating it may be overbought in the short term, which is a risk to consider.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.